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Abstract
Background: The Lewisx trisaccharide, also referred to as the CD15 antigen, is a diagnostic marker used to
distinguish Hodgkin’s lymphoma from other lymphocytic cancers. However, the role of such fucosylated structures
remains poorly understood, in part because carriers of Lewisx structures on Hodgkin’s Reed-Sternberg cells have
not been identified.
Methods: GalMBP, an engineered carbohydrate-recognition protein that binds selectively to oligosaccharides with
paired terminal galactose and fucose residues, has been used in conjunction with proteomic and glycomic analysis
to identify glycoprotein carriers of Lewisx and related glycan structures in multiple Hodgkin’s Reed-Sternberg cell
lines.
Results: Multiple glycoproteins that bind to GalMBP and carry CD15/Lewisx have been identified in a panel of six
Reed-Sternberg cell lines. The most commonly identified Lewisx-bearing glycoproteins are CD98hc, which was
found in all six cell lines tested, and intercellular adhesion molecule-1 and DEC-205, which were detected in five
and four of the lines, respectively. Thus, several of the most prominent cell adhesion molecules on the lymphomas
carry this characteristic glycan epitope. In addition, the Hodgkin’s Reed-Sternberg cell lines can be grouped into
subsets based on the presence or absence of less common Lewisx-bearing glycoproteins.
Conclusions: CD98 and intercellular adhesion molecule-1 are major carriers of CD15/Lewisx on Reed-Sternberg
cells. Binding of DC-SIGN and other glycan-specific receptors to the Lewisx epitopes on CD98 and intercellular
adhesion molecule-1 may facilitate interaction of the lymphoma cells with lymphocytes and myeloid cells in lymph
nodes.
Background
The Lewisx blood group epitope, also referred to as the
CD15 antigen, has been reported on many different can-
cers and cancer cell lines including Hodgkins lympho-
mas, a common form of lymphocytic cancer. The
presence of Lewisx has been used as a marker for the
neoplastic tumour cells of Hodgkins lymphoma, referred
to as Hodgkins Reed-Sternberg (HRS) cells. HRS cells
form a relatively small population of the tumour mass,
with the remaining cells consisting of non-neoplastic
reactive cells including T lymphocytes, granulocytes,
macrophages and plasma cells [1,2]. Crosslinking of
HRS cell-surface molecules containing Lewisx, using
anti-Lewisx antibodies, stimulates cellular signaling
through the tyrosine phosphorylation of proteins includ-
ing c-Cbl [3], suggesting that identification of protein
carriers of Lewisx on HRS cells may provide insight into
how cellular activation is achieved.
The C-type (Ca2+-dependent) carbohydrate-recogni-
tion domain of serum mannose-binding protein, which
normally binds to mannose-containing oligosaccharides
characteristic of pathogens, can be re-engineered to
bind galactose-containing glycans [4,5]. Glycan array
analysis reveals that the modified protein, referred to as
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galactose-specific mannose-binding protien (GalMBP),
binds preferentially to oligosaccharides in which term-
inal galactose residues are adjacent to terminal fucose
residues, as in the Lewisx blood group epitope [6]. The
specificity of GalMBP indicated that it would be a useful
tool for probing the way that Lewisx is presented on the
surface of Reed-Sternberg cells.
By combining affinity purification on immobilized
GalMBP with glycomics and proteomics, several cell
surface molecules on HRS cells have been found to bear
the Lewisx epitope, with the heavy chain of CD98 being
a common carrier on multiple HRS cell lines.
Methods
Cell culture
HRS cell lines L-428, KMH-2, L-1236, L-540, HDLM-2
and U-HO1 were purchased from the DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen
GmbH), Braunschweig, Germany, which provided char-
acterization using antibody reactivity of cell surface mar-
kers, PCR of minisatellite markers, isoelectric focusing of
malate dehydrogenase and aspartate aminotransferase,
and cytogenetics. Cell lines L-428, KM-H2 and L-1236
were grown in RPMI-1640 medium supplemented with
10% fetal calf serum, 2 mM glutamine, 100 U/ml penicil-
lin, and 100 μg/ml streptomycin. Cell lines L-540 and
HDLM-2 were grown in the same medium but with 20%
fetal calf serum. Cell line U-HO1 was grown in 1:4
Iscove’s modified Dulbecco’s medium:RPMI-1640 med-
ium supplemented with 20% fetal calf serum, 2 mM glu-
tamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.
Purification of membrane glycoproteins on immobilized
GalMBP
Cells grown to 0.5 - 1 × 106 cells/ml in 100 ml of med-
ium were harvested by centrifugation at 450 × g for
2 min, washed twice in 10 ml of phosphate-buffered sal-
ine, resuspended in 10 ml of cell lysis buffer (150 mM
NaCl; 25 mM Tris-Cl, pH 7.8; 2 mM CaCl2; 1% Triton
X-100) and protease inhibitors (Cocktail mix 1, Merck,
Nottingham, UK), sonicated for 10 s and incubated on
ice for 30 min. Lysate was precleared by centrifugation
at 100,000 × g for 15 min at 4°C and passed over 2-ml
GalMBP-agarose columns [6] that were washed with
5 ml of loading buffer (150 mM NaCl; 25 mM Tris-Cl,
pH 7.8; 2 mM CaCl2; 0.1% Triton X-100) and eluted
with 1-ml fractions of elution buffer (150 mM NaCl;
25 mM Tris-Cl, pH 7.8; 2.5 mM EDTA; 0.1% Triton
X-100). Pooled elution fractions were brought to
25 mM CaCl2 and passed over a second GalMBP col-
umn that was washed with 5 ml of high salt buffer
(1.25 M NaCl; 25 mM Tris-Cl, pH 7.8; 25 mM CaCl2;
0.1% Triton X-100) and 5 ml of loading buffer followed
by elution as above.
Gel analysis of GalMBP ligands
Samples were analyzed on 15% SDS-polyacrylamide gels
that were electroblotted onto Protran nitrocellulose
membranes (Whatman Plc, Kent, UK) [7]. For probing
with 125I-GalMBP [8], membranes were blocked over-
night at 4°C with 2% hemoglobin in binding buffer
(150 mM NaCl; 25 mM Tris-Cl, pH 7.8; 2 mM CaCl2)
and incubated with 125I-GalMBP for 2 h at room tem-
perature with gentle shaking in the same buffer. Follow-
ing four washes with binding buffer, radioactivity on
membranes was detected using a Phosphorimager SI
from Molecular Dynamics (Sunnyvale, USA). Probing
with anti-Lewisx antibodies MCS-1 (Quest Biomedicals
Ltd, West Midlands, UK) and FC-2.15 was performed as
previously described [9].
Glycan analysis
N-linked glycans released from tryptic peptides by diges-
tion with peptide:N-glycosidase F were purified using a
Sep-Pak C18 reverse phase cartridge and permethylated
using the anhydrous sodium hydroxide method [10].
Following a further round of Sep-Pak purification, per-
methylated glycans were dissolved in 10 μl of methanol:
H2O (4:1), mixed with an equal volume of 2,5-dihydrox-
ybenzoic acid matrix and subjected to matrix-assisted
laser desorption ionization mass spectrometry (MALDI
MS) profiling with further tandem mass spectrometry
(MS/MS) analysis of selected ions [11].
Proteomic analysis
Proteins resolved on SDS-polyacrylamide gels were
excised, and subjected to proteomic analysis by in-gel
trypsin digestion [6] using MALDI MS profiling comple-
mented with MS/MS sequencing of the ten most abun-
dant ions in each sample on an Applied BioSystems
4800 MALDI tandem time-of-flight mass spectrometer.
For in-solution trypsin digestion, fractions were precipi-
tated with trichloroacetic acid, dissolved in 8 M urea
containing 10 mM HEPES, pH 8.0, reduced, alkylated,
and digested in solution with trypsin [12]. Tryptic pep-
tides were dried, desalted, and purified by nano-liquid
chromatography using a 15 μm × 15 cm Pepmap analy-
tical C18 nanocapillary column on an Ultimate 3000
liquid chromatography system (LC Packings, Dionex,
Sunnyvale, USA) eluted with a gradient from 8-45%
acetonitrile over 60 min at a flow rate of 0.3 μl/min [6].
Eluted peptides were detected by MALDI MS profiling
and sequenced by MS/MS.
Results
Affinity purification of glycoproteins that bear Lewisx
structures on HRS cells
L-428 cells, which are model HRS cells on which Lewisx
expression has been documented using monoclonal
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antibodies [3], were used to test the utility of GalMBP
for purification of glycoproteins that carry Lewisx. Gly-
coproteins in detergent extracts of L-428 cell that
bound to immobilized GalMBP in the presence of Ca2+
were eluted with EDTA and analyzed by SDS-polyacry-
lamide gel electrophoresis, demonstrating the presence
of multiple potential ligands covering a broad distribu-
tion of molecular weights ranging from 48 kDa to well
over 175 kDa (Figure 1A). Probing of western blots con-
firmed that these eluted glycoproteins bind to radiola-
belled GalMBP (Figure 1B) and the presence of glycans
containing Lewisx was also demonstrated by probing the
blots with two anti-Lewisx antibodies (Figure 1C,D).
MALDI MS analysis of N-glycans released from the pool
of glycoproteins eluted from the GalMBP column revealed
the presence of glycans containing up to 3 fucose residues
(Figure 2A) and MS/MS analysis of the major molecular
ions led to identification of bi-, tri- and tetra-antennary
complex glycans that are terminally fucosylated
(Figure 2B). These glycans gave fragment ions at m/z 660,
corresponding to terminal FucHexHexNAc, which would
represent terminal Lewisa or Lewisx trisaccharides
(Figure 2B). The MS/MS fragmentation also provided evi-
dence that a portion of these termini are in the form
Lewisx epitopes, consistent with the antibody binding data.
Comparing related glycan structures indicates that a sub-
stantial proportion of each class of branched structure
contains terminal fucosylated structures. For example, the
relative intensities of the molecular ions at m/z 2416 and
2591, which correspond to bi-antennary glycans contain-
ing two and three fucose residues, is comparable to that of
the molecular ion m/z 2243, corresponding to a bi-antenn-
ary glycan without terminal fucosylation. Larger glycans
present include tetra-antennary structures that contain
one or two fucosylated branches and glycans with poly-N-
acetyllactosamine extensions, many of which also bear
terminal fucose residues.
Proteomic identification of GalMBP ligands on L-428 cells
The identity of glycoproteins that bear this spectrum of
Lewisx-containing glycans was initially investigated by
proteomic analysis of proteins fractioned by SDS-polya-
crylamide gel electrophoresis. Despite the presence of
overlapping bands, probably due to heterogeneity of gly-
cans present on individual glycoproteins, multiple glyco-
proteins were identified, including the dendritic and
epithelial cell receptor DEC-205 (CD205) and intercellu-
lar adhesion molecule 1 (ICAM-1) (Figure 3 and Addi-
tional file 1). DEC-205 and ICAM-1 are both heavily
glycosylated proteins known to be expressed in HRS cells
[13,14]. The heavy chain of the cell surface molecule
CD98 (CD98hc) was identified across a region of the gel
between approximately 75 and 100 kDa and the accom-
panying small chain LAT1 was also detected, but below
confidence levels for the analysis (Additional file 1). Both
LAT1 and the ATB(0) protein, which was detected just
above the confidence threshold, are amino acid transpor-
ters. The average distance between glycosylated aspara-
gine residues in CD98hc is approximately 26 Å, so that
terminal galactose residues on N-linked glycans attached
at these sites could bridge the distance between binding
sites in a GalMBP trimer [15], which may contribute to
the effectiveness with which CD98hc can be isolated
from multiple HRS cell lines using GalMBP.
In an alternative approach to the proteomic analysis,
glycoproteins purified on GalMBP were identified
directly by trypsin digestion of the pooled elution frac-
tions. The resulting peptides were purified by liquid
chromatography and individual peptides were identified
by MALDI MS analysis and sequenced by collision-
induced dissociation followed by tandem mass spectro-
metry. In agreement with the in-gel analysis, CD98hc,
DEC-205 and ICAM-1 were identified with the highest
levels of confidence (Additional file 2), thus validating
the batch digestion approach as a means of glycoprotein
identification. Because of the increased sensitivity and
reduced background of the batch analysis, several addi-
tional glycoproteins not detected by the in-gel analysis,
including cell-surface receptors CD70, CD86, CD147 and
HLA-DR, were also identified in the elution fractions.
Identification of common GalMBP ligands on HRS cell
lines
Based on the results of the glycomic and proteomic ana-
lysis of the L-428 cells, fractionation on GalMBP
Figure 1 Analysis of GalMBP ligands from L-428 cells with anti-
Lewisx antibodies. Elution fractions from solubilized L-428 cells
purified over a column of immobilized GalMBP were analyzed on
15% SDS-polyacrylamide gels followed by Coomassie blue staining
or electroblotting onto nitrocellulose and probing with anti-Lewisx
antibodies and radiolabelled GalMBP. The different relative
intensities of some of the bands suggest that GalMBP and the
antibodies bind differentially to glycans.
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followed by batchwise proteomic analysis was used for
screening multiple cell lines to characterize the spec-
trum of glycoprotein carriers of Lewisx in Hodgkin’s
lymphoma. Analysis of a panel of five further HRS cell
lines showed a pattern of common Lewisx carrier glyco-
proteins found in the majority of the cell lines (Figure 4
and Additional file 2). The most commonly identified
glycoproteins were CD98hc, identified in all of the cell
lines, ICAM-1, found in all except one line and DEC-205,
detected in four of the six lines. These results suggest
that these proteins often present Lewisx structures and
may indicate a potential role for the glycan structure in
Figure 2 Mass spectrometric analysis of N-linked glycans from GalMBP ligands on L-428 cells. Purified GalMBP ligands were digested with
trypsin and N-linked glycans were released by peptide:N-glycosidase F. N-linked glycans were permethylated and subjected to Sep-Pak
purification. A. The MALDI MS spectrum of one of the elution fractions from the Sep-Pak is shown. All labeled ions were subjected to MS/MS
analysis. The schemes for each ion represent the most likely structure based on the fit between the calculated composition and the m/z (z = 1)
ratio of the ions detected, taking into account the biosynthetic pathways of N-glycosylation in addition to the MS and MS/MS data collected.
Structures in red boxes contain terminal fucose residues. B. An example of the MALDI MS/MS spectra, showing fragmentation of the 2591
molecular ion. The presence of major fragment ions at 1954 and 660 confirms the presence of terminal Lewisx or Lewisa structures. Specific
evidence for the presence of Lewisx structures is provided by elimination of fucose from the 3 position of GlcNAc to form the 2385 fragment
ion. The presence of unfucosylated glycans that are suboptimal ligands for GalMBP, as well as high-mannose oligosaccharides that do not bind
GalMBP at all, is presumed to reflect the presence of heavily glycosylated glycoproteins that also contain complex-type glycans bound by
GalMBP as previously observed for breast cancer cells [6].
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the function of these proteins on HRS cells. However, the
data also indicated that there is variability between cell
lines and that they can be grouped based on the presence
of different sets of carrier glycoproteins in the GalMBP
elution fractions (Figure 4), although each cell line
appears to have some unique characteristics.
Discussion
Glycoproteins identified in HRS cells by GalMBP affinity
chromatography provide potential clues about the role
of Lewisx-containing glycans in the pathology of Hodg-
kin’s lymphoma. Two of the major ligands identified,
CD98hc and ICAM-1, participate in integrin-mediated
adhesion [16]. Binding of Lewisx-bearing glycans on
these molecules by glycan-specific receptors on the sur-
faces of lymphocytes and myeloid cells may facilitate
their binding to counter-receptors on target cells by
bringing them into close proximity to their ligands. For
example, DC-SIGN binding to Lewisx-containing glycans
[17], could initiate interactions between HRS cells and
dendritic cells. The lysosome-associated membrane pro-
teins LAMP1 and LAMP2 bind to the GalMBP columns.
These heavily glycosylated proteins predominantly reside
in lysosomes, but have also been implicated in adhesion
of activated lymphocytes to endothelial cells [18].
Identification of ICAM-1 and CD98hc as major car-
riers of Lewisx structures may explain, in part, why anti-
bodies specific to Lewisx structures are able to activate
tyrosine kinase signaling pathways in HRS cell lines [3],
because both of these receptors can transmit activation
signals following binding by extracellular ligands [19,20].
Lewisx-containing glycoproteins on HRS cells could act
in a manner analogous to the way that Lewisx structures
on parasites such as Schistosoma mansoni induce a Th2
response by binding to C-type lectins and modulating
cytokine production [21]. For example, the presence of
Lewisx-bearing glycans on glycoproteins that are
involved in co-stimulation of CD4+ T cells could facili-
tate polarization of activated T cells towards a Th2
response [22], thus maintaining an inflammatory micro-
environment within the tumor and suppressing potential
anti-tumor activity of Th1 cells.
The ability to purify both major and minor popula-
tions of Lewisx-containing glycoproteins on immobilized
GalMBP has revealed differences in the panel of glyco-
proteins purified from each cell line. These variations
define subsets of HRS cell lines and suggest that
GalMBP may be used to classify HRS cell lines into sub-
groups that present Lewisx on specific protein scaffolds.
Conclusions
Affinity purification on immobilized GalMBP combined
with glycomics and proteomics has been validated as a
means of characterizing glycoproteins on HRS cells that
bear the Lewisx epitope. These glycoproteins, including
CD98 and ICAM-1, are potential targets for both anti-
Figure 3 GalMBP ligands from L-428 cells. Cell extracts were
fractionated on columns of immobilized GalMBP. Proteins
present in elution fractions from the GalMBP column were resolved
on 15% SDS-polyacrylamide gels, excised, and subjected to
proteomic analysis by in-gel trypsin digestion. Proteins present in
bands 1-16, identified by mass spectrometry following trypsin
digestion, are listed in the right hand column and in Additional file 1.
Figure 4 Glycoproteins found in multiple HRS cell lines. Proteins
present in at least two cell lines in Additional file 2 are indicated by
dots. Colored boxes highlight subgroups within the panel of cell
lines.
Powlesland et al. BMC Biochemistry 2011, 12:13
http://www.biomedcentral.com/1471-2091/12/13
Page 5 of 6
CD15 antibodies and for endogenous glycan-binding
receptors.
Additional material
Additional file 1: MALDI MS analysis of tryptic fragments from L-
428 cell proteins. Bands in Figure 2 were identified by MS and MS/MS
analysis of tryptic fragments and searching of the SwissProt protein
database.
Additional file 2: GalMBP ligands from HRS cell lines identified by
in-solution digestion followed by liquid chromatography and MS/
MS analysis. The SwissProt database was searched for sequences
consistent with the MS/MS fragment ions for cell lines L-428, HDLM-2,
KM-H2, L-1236, U-H01, and L-540.
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